Dépistage de l’infection à SARS-CoV-2 chez les voyageurs - Quelle approche pour évaluer le risque de transmis [SARS-CoV-2 screening in travelers: what approach to assess transmission risk ?]
Fiche du document
5 mai 2021
- doi: 10.53738/REVMED.2021.17.737.0866
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2021.17.737.0866
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33950587
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7C98889AD6913
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Infectious diseasesCiter ce document
A. Allgöwer et al., « Dépistage de l’infection à SARS-CoV-2 chez les voyageurs - Quelle approche pour évaluer le risque de transmis [SARS-CoV-2 screening in travelers: what approach to assess transmission risk ?] », Serveur académique Lausannois, ID : 10.53738/REVMED.2021.17.737.0866
Métriques
Partage / Export
Résumé
Before a trip, a screening for SARS-CoV-2 infection by RT-PCR is often required and raises the problem of detection of residual viral RNA at distance from the acute infection (post-Covid). At the University Hospital of Geneva, we developed an expertise to distinguish acute from post-Covid infections. Between October and December 2020, 30% of the people tested positive were able to travel because the result corresponded to post-Covid and 65% were put in isolation because of an acute infection with a risk of transmission. To overcome the detection of residual viral RNA by RT-PCR, a rapid antigenic test would be an interesting and less expensive alternative. It could also be performed a few hours before departure.